A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.

BMC Cancer · 2025 · PMC12362974 · PMID 40826034

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

did not reach statistical significancep = 0.15not close (p > 0.1)

Again, the difference did not reach statistical significance ( p = 0.15), but the marginal improvement in OS supports Ribociclib’s potential benefit in prolonging life in this population (see Fig. 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.